333 related articles for article (PubMed ID: 29930721)
1. The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.
Hsu WT; Huang CY; Yen CYT; Cheng AL; Hsieh PCH
Theranostics; 2018; 8(12):3176-3188. PubMed ID: 29930721
[No Abstract] [Full Text] [Related]
2. Lapatinib induces mitochondrial dysfunction to enhance oxidative stress and ferroptosis in doxorubicin-induced cardiomyocytes via inhibition of PI3K/AKT signaling pathway.
Sun L; Wang H; Xu D; Yu S; Zhang L; Li X
Bioengineered; 2022 Jan; 13(1):48-60. PubMed ID: 34898356
[TBL] [Abstract][Full Text] [Related]
3. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity.
Milano G; Biemmi V; Lazzarini E; Balbi C; Ciullo A; Bolis S; Ameri P; Di Silvestre D; Mauri P; Barile L; Vassalli G
Cardiovasc Res; 2020 Feb; 116(2):383-392. PubMed ID: 31098627
[TBL] [Abstract][Full Text] [Related]
4. Protection against Doxorubicin-Induced Cardiotoxicity through Modulating iNOS/ARG 2 Balance by Electroacupuncture at PC6.
Wang J; Yao L; Wu X; Guo Q; Sun S; Li J; Shi G; Caldwell RB; Caldwell RW; Chen Y
Oxid Med Cell Longev; 2021; 2021():6628957. PubMed ID: 33824696
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitro.
Wei S; Ma W; Yang Y; Sun T; Jiang C; Liu J; Zhang B; Li W
Biochem Pharmacol; 2023 Aug; 214():115662. PubMed ID: 37331637
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib combined with doxorubicin causes dose-dependent cardiotoxicity partially through activating the p38MAPK signaling pathway in zebrafish embryos.
Du K; Liu Y; Zhang L; Peng L; Dong W; Jiang Y; Niu M; Sun Y; Wu C; Niu Y; Ding Y
Biomed Pharmacother; 2024 Jun; 175():116637. PubMed ID: 38653111
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE
Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049
[TBL] [Abstract][Full Text] [Related]
9. Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells.
Nemade H; Chaudhari U; Acharya A; Hescheler J; Hengstler JG; Papadopoulos S; Sachinidis A
Arch Toxicol; 2018 Apr; 92(4):1507-1524. PubMed ID: 29397400
[TBL] [Abstract][Full Text] [Related]
10. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
11. The prostaglandin agonist beraprost aggravates doxorubicin-mediated apoptosis by increasing iNOS expression in cardiomyocytes.
Lian WS; Chiou HC; Lin H; Chen JJ; Cheng CF
Curr Vasc Pharmacol; 2015; 13(1):54-63. PubMed ID: 23628005
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity.
Ibrahim MA; Ashour OM; Ibrahim YF; El-Bitar HI; Gomaa W; Abdel-Rahim SR
Pharmacol Res; 2009 Nov; 60(5):373-81. PubMed ID: 19467331
[TBL] [Abstract][Full Text] [Related]
13. Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4.
Golforoush PA; Narasimhan P; Chaves-Guerrero PP; Lawrence E; Newton G; Yan R; Harding SE; Perrior T; Chapman KL; Schneider MD
Sci Rep; 2020 Jul; 10(1):12060. PubMed ID: 32694738
[TBL] [Abstract][Full Text] [Related]
14. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity.
Anjos M; Fontes-Oliveira M; Costa VM; Santos M; Ferreira R
Life Sci; 2021 Sep; 280():119760. PubMed ID: 34166713
[TBL] [Abstract][Full Text] [Related]
15. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth.
Li M; Sala V; De Santis MC; Cimino J; Cappello P; Pianca N; Di Bona A; Margaria JP; Martini M; Lazzarini E; Pirozzi F; Rossi L; Franco I; Bornbaum J; Heger J; Rohrbach S; Perino A; Tocchetti CG; Lima BHF; Teixeira MM; Porporato PE; Schulz R; Angelini A; Sandri M; Ameri P; Sciarretta S; Lima-Júnior RCP; Mongillo M; Zaglia T; Morello F; Novelli F; Hirsch E; Ghigo A
Circulation; 2018 Aug; 138(7):696-711. PubMed ID: 29348263
[TBL] [Abstract][Full Text] [Related]
16. Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.
Seemann I; te Poele JA; Song JY; Hoving S; Russell NS; Stewart FA
Breast Cancer Res Treat; 2013 Oct; 141(3):385-95. PubMed ID: 24091769
[TBL] [Abstract][Full Text] [Related]
17. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients.
Haupt LP; Rebs S; Maurer W; Hübscher D; Tiburcy M; Pabel S; Maus A; Köhne S; Tappu R; Haas J; Li Y; Sasse A; Santos CCX; Dressel R; Wojnowski L; Bunt G; Möbius W; Shah AM; Meder B; Wollnik B; Sossalla S; Hasenfuss G; Streckfuss-Bömeke K
Basic Res Cardiol; 2022 Mar; 117(1):13. PubMed ID: 35260914
[TBL] [Abstract][Full Text] [Related]
20. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.
Maillet A; Tan K; Chai X; Sadananda SN; Mehta A; Ooi J; Hayden MR; Pouladi MA; Ghosh S; Shim W; Brunham LR
Sci Rep; 2016 May; 6():25333. PubMed ID: 27142468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
